Daily Brief Health Care: Inspire Medical Systems Inc, Ascentage Pharma Group Corp, Encompass Health , VolitionRX and more

• Inspire Medical Systems reported a promising third quarter in 2024, demonstrating significant revenue growth and improvements in profitability.
• The company’s revenue for the third quarter was $203.2 million, up 33% compared to the same period in 2023.
• This growth was predominantly driven by the increased adoption of Inspire therapy, reflected in the expansion into 66 new implanting centers and growth in 13 new U.S. sales territories.

• Ascentage has filed with the SEC to raise up to US$100 million in a US IPO. We think its future market value is expected to surpass that of Hutchmed.
• The outlook of olverembatinib is clear. Takeda can give more possibilities to olverembatinib. 2025 Sales of olverembatinib is expected to reach RMB500 million.Market value contribution from olverembatinib is US$1-1.5 billion. 
• Investors have higher expectations on APG-2575 to be out-licensed to MNCs. We think the peak sales of APG-2575 is expected to surpass that of olverembatinib in overseas markets. 

• Encompass Health reported a solid third quarter 2024, marked by notable increases in key financial metrics.
• The company experienced an 11.9% rise in revenue to $1.35 billion and a 13.4% increase in adjusted EBITDA to $269.3 million.
• The total discharges grew by 8.8%, with same-store discharges up by 6.8%.

Edison Investment Research is terminating coverage on VolitionRx (VNRX), Murray Income Trust (MUT) and NioCorp Developments (NB). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.